{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-22-000090","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.130875+00:00","generated_at":"2026-06-22T04:17:42.330068+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Instil Bio presents CoStAR platform data at SITC; ITIL-306 Phase 1 ongoing","bullets":["Pre-clinical data showed CoStAR amplified T-cell responses across all FRα expression levels, supporting clinical exploration in multiple solid tumors.","First patient dosed in ITIL-306 Phase 1 study in October 2022; evaluating safety and feasibility in advanced solid tumors.","Treatment regimen is free of high-dose interleukin-2.","Posters presented at SITC 2022; available on company website."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-22-000090","json":"https://secwatch.observer/filing/0001789769-22-000090.json","markdown":"https://secwatch.observer/filing/0001789769-22-000090.md","text":"https://secwatch.observer/filing/0001789769-22-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976922000090/0001789769-22-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976922000090/til-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:17:42.330068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}